Two sizable companies and a handful of small Asian issuers were listed in the US this past week. Read more here.

Despite new medication, cystic fibrosis often leads to permanent lung damage. Working with an international team, researchers ...

Cystic fibrosis is a genetic disorder that changes a vital protein in the body, causing a buildup of thick and sticky mucus, ...

Researchers have been trying for decades to stop the cells that damage the lung in people with pulmonary fibrosis. Now a team ...

The Massachusetts-based biotech plans to use the funds to push its candidates into mid-stage clinical trials in a space ...

Experiments and modeling reveal the unexpected structure that can be seen in bacteria grown in mucus samples and biofilms. Scientists at Caltech and Princeton University have discovered that ...

Explore the courageous journey of Claire Wineland as she shared her life with cystic fibrosis, inspiring many. The 30 greatest footballers of the 21st century – ranked World’s largest digital ...

In December, the FDA approved Vertex’s vanzacaftor, tezacaftor and deutivacaftor (Alyftrek) for the treatment of cystic fibrosis in patients with at least one F508del mutation or another ...

Eli Lilly is making a play for the idiopathic pulmonary fibrosis (IPF) market, offering Mediar Therapeutics $99 million in upfront and near-term payments for global rights to an asset that is ...

What is a cystic hygroma? A cystic hygroma — or lymphangioma — is a birth defect that appears as a sac-like structure with a thin wall that most commonly occurs in the head and neck area of an infant.